{
  "id": [
    "28072684"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "28072684"
  ],
  "pmcid": [
    "PMC5228644"
  ],
  "doi": [
    "10.1097/md.0000000000005321"
  ],
  "title": [
    "Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs."
  ],
  "authorString": [
    "Lee SH, Jin YJ, Shin JY, Lee JW."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Lee SH"
          ],
          "firstName": [
            "Seung Ho"
          ],
          "lastName": [
            "Lee"
          ],
          "initials": [
            "SH"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, South Korea."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Jin YJ"
          ],
          "firstName": [
            "Young-Joo"
          ],
          "lastName": [
            "Jin"
          ],
          "initials": [
            "YJ"
          ]
        },
        {
          "fullName": [
            "Shin JY"
          ],
          "firstName": [
            "Jun Young"
          ],
          "lastName": [
            "Shin"
          ],
          "initials": [
            "JY"
          ]
        },
        {
          "fullName": [
            "Lee JW"
          ],
          "firstName": [
            "Jin-Woo"
          ],
          "lastName": [
            "Lee"
          ],
          "initials": [
            "JW"
          ]
        }
      ]
    }
  ],
  "journalInfo": [
    {
      "issue": [
        "1"
      ],
      "volume": [
        "96"
      ],
      "journalIssueId": [
        "2514143"
      ],
      "dateOfPublication": [
        "2017 Jan"
      ],
      "monthOfPublication": [
        "1"
      ],
      "yearOfPublication": [
        "2017"
      ],
      "printPublicationDate": [
        "2017-01-01"
      ],
      "journal": [
        {
          "title": [
            "Medicine"
          ],
          "ISOAbbreviation": [
            "Medicine (Baltimore)"
          ],
          "medlineAbbreviation": [
            "Medicine (Baltimore)"
          ],
          "NLMid": [
            "2985248R"
          ],
          "ISSN": [
            "0304-5412"
          ],
          "ESSN": [
            "1536-5964"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2017"
  ],
  "pageInfo": [
    "e5321"
  ],
  "abstractText": [
    "In this new era of highly effective oral antiviral drugs for chronic hepatitis C virus (HCV), indications for antiviral treatment may be extendable. This study undertaken to identify suitable candidates for peg-interferon plus ribavirin (PEG-IFN/RBV) treatment by evaluating hepatocellular carcinoma (HCC) risk in patients with chronic HCV treated or not with PEG-IFN/RBV.This large-scale retrospective study was conducted on 1176 patients with chronic HCV without a history of HCC (treatment group [n = 489] and no-treatment group [n = 687]). In the treatment group, patients treated with PEG-IFN/RBV were dichotomized based on the achievement of sustained virologic response (SVR) into SVR (+) and SVR (-) groups.Median follow-up for all study subjects was 31 months (range 6-144 months). Three-year cumulative HCC development rates in the SVR (+) (1.1%) and SVR (-) (8.6%) subgroups were significantly lower than in the no-treatment group (13.5%) (P < 0.01 and P < 0.01, respectively). In all study subjects, presence of cirrhosis (hazard ratio [HR], 9.92, P < 0.01), age (HR 1.03, P < 0.01), SVR (-) (HR 7.02, P < 0.01), and no-treatment (HR 6.76, P < 0.01) were found to be independent risk factors of HCC development. In the treatment group, age, the presence of cirrhosis, and SVR (-) were predictors of HCC development. In the no-treatment group, age, male, and the presence of cirrhosis were independent predictors for HCC development.HCC risk increased in patients with chronic HCV with older age, cirrhosis, SVR (-) after PEG-IFN/RBV treatment, and no PEG-IFN/RBV treatment. Active antiviral therapy based on highly effective oral drugs needs to be considered in these patients."
  ],
  "affiliation": [
    "Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, South Korea."
  ],
  "publicationStatus": [
    "ppublish"
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Print"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "research-article",
        "Journal Article"
      ]
    }
  ],
  "meshHeadingList": [
    {
      "meshHeading": [
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Humans"
          ]
        },
        {
          "majorTopic_YN": [
            "Y"
          ],
          "descriptorName": [
            "Hepacivirus"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DE"
                  ],
                  "qualifierName": [
                    "drug effects"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "IP"
                  ],
                  "qualifierName": [
                    "isolation & purification"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "Y"
          ],
          "descriptorName": [
            "Hepatitis C, Chronic"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DT"
                  ],
                  "qualifierName": [
                    "drug therapy"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "EP"
                  ],
                  "qualifierName": [
                    "epidemiology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "VI"
                  ],
                  "qualifierName": [
                    "virology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "Y"
          ],
          "descriptorName": [
            "Carcinoma, Hepatocellular"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DI"
                  ],
                  "qualifierName": [
                    "diagnosis"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "EP"
                  ],
                  "qualifierName": [
                    "epidemiology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "PA"
                  ],
                  "qualifierName": [
                    "pathology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "Y"
          ],
          "descriptorName": [
            "Liver Neoplasms"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DI"
                  ],
                  "qualifierName": [
                    "diagnosis"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "EP"
                  ],
                  "qualifierName": [
                    "epidemiology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "PA"
                  ],
                  "qualifierName": [
                    "pathology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Liver Cirrhosis"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "EP"
                  ],
                  "qualifierName": [
                    "epidemiology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Polyethylene Glycols"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Interferon-alpha"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Recombinant Proteins"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Ribavirin"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Antiviral Agents"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Prognosis"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Risk Assessment"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Risk Factors"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Retrospective Studies"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Age Factors"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Adult"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Aged"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Middle Aged"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Female"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Male"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Republic of Korea"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "EP"
                  ],
                  "qualifierName": [
                    "epidemiology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Interferon alpha-2"
          ]
        }
      ]
    }
  ],
  "chemicalList": [
    {
      "chemical": [
        {
          "name": [
            "Antiviral Agents"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Interferon-alpha"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Recombinant Proteins"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Ribavirin"
          ],
          "registryNumber": [
            "49717AWG6K"
          ]
        },
        {
          "name": [
            "peginterferon alfa-2b"
          ],
          "registryNumber": [
            "G8RGG88B68"
          ]
        },
        {
          "name": [
            "Polyethylene Glycols"
          ],
          "registryNumber": [
            "3WJQ0SDW1A"
          ]
        },
        {
          "name": [
            "Interferon alpha-2"
          ],
          "registryNumber": [
            "0"
          ]
        }
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "AIM"
          ],
          "name": [
            "Core clinical journals"
          ]
        },
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1097/MD.0000000000005321"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC5228644"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC5228644?pdf=render"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1097/md.0000000000005321"
          ]
        }
      ]
    }
  ],
  "commentCorrectionList": [
    {
      "commentCorrection": [
        {
          "id": [
            "31305661"
          ],
          "source": [
            "MED"
          ],
          "reference": [
            "Medicine (Baltimore). 2017 May 19;96(20):e6958"
          ],
          "type": [
            "Erratum in"
          ],
          "orderIn": [
            "1"
          ]
        },
        {
          "id": [
            "31305738"
          ],
          "source": [
            "MED"
          ],
          "reference": [
            "Medicine (Baltimore). 2017 Feb 17;96(7):e6193"
          ],
          "type": [
            "Erratum in"
          ],
          "orderIn": [
            "2"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "N"
  ],
  "citedByCount": [
    "4"
  ],
  "hasData": [
    "N"
  ],
  "hasReferences": [
    "Y"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "N"
  ],
  "license": [
    "cc by-nc-nd"
  ],
  "authMan": [
    "N"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "nihAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "N"
  ],
  "dateOfCompletion": [
    "2017-02-16"
  ],
  "dateOfCreation": [
    "2017-01-11"
  ],
  "firstIndexDate": [
    "2017-01-13"
  ],
  "fullTextReceivedDate": [
    "2017-01-31"
  ],
  "dateOfRevision": [
    "2018-12-02"
  ],
  "firstPublicationDate": [
    "2017-01-01"
  ]
}